FOXO1 and ovarian carcinoma: In ovarian carcinoma preclinical models, FoxO1 contributes to the efficacy of the combination of cisplatin and selinexor, a selective inhibitor of the nuclear export receptor (XPO1)/Chromosome Region Maintenance-1 (CRM1) [63], because a stronger synergistic interaction was observed in cells expressing FoxO1 than in cells in which FoxO1 was down-regulated.